Brodalumab/Brodalumab

Brodalumab is a human monoclonal antibody that inhibits interleukin-17 (IL-17) pathway by binding to IL-17 receptor. In clinical trials, a PASI75 response has been achieved in 82-84% of the patients at week 12. It was shown to be effective also in generalized pustular and erythrodermic psoriasis. As with other IL-17 inhibitors, brodalumab should be used with caution in patients with inflammatory bowel disease. Keywords: Anti-IL-17RA, brodalumab, psoriasis Brodalumab interlokin-17 (IL-17) reseptorune baglanarak IL-17 yolagini inhibe eden insan kaynakli bir monoklonal antikordur. Klinik arajtirmalarda, 12. haftada hastalarin %82 ila 84'unde PAJI75 yaniti elde edilmijtir. Generalize pustuler ve eritrodermik psoriasiste de etkili oldugu gosterilmijtir. Diger IL-17 inhibitorlerinde oldugu gibi inflamatuar barsak hastaligi olanlarda dikkatli kullanilmalidir. Anahtar Kelimeler: Anti-IL-17RA, brodalumab, psoriasis